Inspire Medical Systems, Inc. (INSP)
USD 186.97
(-1.96%)
USD 186.97
(-1.96%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -17.06 Million USD | 5.45% |
| 2022 | -39.69 Million USD | -6.9% |
| 2021 | -38.62 Million USD | 27.52% |
| 2020 | -53.15 Million USD | -76.85% |
| 2019 | -29.68 Million USD | -67.8% |
| 2018 | -18.13 Million USD | -19.72% |
| 2017 | -15.47 Million USD | 9.63% |
| 2016 | -17.12 Million USD | 12.88% |
| 2015 | -19.65 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -14.37 Million USD | -189.55% |
| 2024 Q2 | 6.48 Million USD | 145.08% |
| 2024 Q3 | 14.31 Million USD | 149.43% |
| 2023 FY | - USD | 5.45% |
| 2023 Q3 | -8.2 Million USD | 50.6% |
| 2023 Q2 | -16.59 Million USD | -9.15% |
| 2023 Q1 | -15.2 Million USD | -564.37% |
| 2023 Q4 | 16.05 Million USD | 295.82% |
| 2022 Q4 | 3.27 Million USD | 121.22% |
| 2022 Q2 | -13.43 Million USD | 14.46% |
| 2022 Q1 | -15.7 Million USD | -756.96% |
| 2022 FY | - USD | -6.9% |
| 2022 Q3 | -15.43 Million USD | -14.85% |
| 2021 Q3 | -9.47 Million USD | 22.55% |
| 2021 FY | - USD | 27.52% |
| 2021 Q1 | -15.43 Million USD | -122.97% |
| 2021 Q2 | -12.22 Million USD | 20.78% |
| 2021 Q4 | -1.83 Million USD | 80.65% |
| 2020 FY | - USD | -76.85% |
| 2020 Q1 | -15.53 Million USD | -82.53% |
| 2020 Q2 | -22.37 Million USD | -44.05% |
| 2020 Q3 | -9.55 Million USD | 57.31% |
| 2020 Q4 | -6.92 Million USD | 27.53% |
| 2019 Q3 | -7.58 Million USD | -8.03% |
| 2019 FY | - USD | -67.8% |
| 2019 Q1 | -7.62 Million USD | -86.5% |
| 2019 Q4 | -8.51 Million USD | -12.2% |
| 2019 Q2 | -7.02 Million USD | 7.93% |
| 2018 Q1 | -5.02 Million USD | -39.19% |
| 2018 Q2 | -5.2 Million USD | -3.62% |
| 2018 Q3 | -3.91 Million USD | 24.87% |
| 2018 Q4 | -4.08 Million USD | -4.5% |
| 2018 FY | - USD | -19.72% |
| 2017 Q1 | -4.06 Million USD | 0.0% |
| 2017 FY | - USD | 9.63% |
| 2017 Q2 | -4.27 Million USD | -5.27% |
| 2017 Q3 | -3.52 Million USD | 17.72% |
| 2017 Q4 | -3.61 Million USD | -2.59% |
| 2016 FY | - USD | 12.88% |
| 2015 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Abbott Laboratories | 10.46 Billion USD | 100.163% |
| Allurion Technologies Inc. | -69.03 Million USD | 75.286% |
| Artivion, Inc. | 38.14 Million USD | 144.728% |
| Avanos Medical, Inc. | 53.2 Million USD | 132.068% |
| Butterfly Network, Inc. | -124.84 Million USD | 86.335% |
| Butterfly Network, Inc. | -124.84 Million USD | 86.335% |
| Bio-Rad Laboratories, Inc. | -608.26 Million USD | 97.195% |
| Boston Scientific Corporation | 3.45 Billion USD | 100.494% |
| Perspective Therapeutics, Inc. | -14.83 Million USD | -14.975% |
| CONMED Corporation | 182.18 Million USD | 109.364% |
| Edwards Lifesciences Corporation | 1.76 Billion USD | 100.965% |
| Paragon 28, Inc. | -36.61 Million USD | 53.406% |
| Glaukos Corporation | -82.11 Million USD | 79.225% |
| Globus Medical, Inc. | 418.23 Million USD | 104.079% |
| Integer Holdings Corporation | 282.05 Million USD | 106.048% |
| Medtronic plc | 9.05 Billion USD | 100.188% |
| Nevro Corp. | -78.31 Million USD | 78.215% |
| Owlet, Inc. | -27.48 Million USD | 37.939% |
| Penumbra, Inc. | 111.99 Million USD | 115.233% |
| Vicarious Surgical Inc. | -69.19 Million USD | 75.344% |
| Smith & Nephew plc | 979 Million USD | 101.743% |
| Sonendo, Inc. | -54.76 Million USD | 68.85% |
| STERIS plc | 1.41 Billion USD | 101.208% |
| Stryker Corporation | 5.16 Billion USD | 100.331% |
| Vapotherm, Inc. | -34.35 Million USD | 50.345% |
| Zimmer Biomet Holdings, Inc. | 2.44 Billion USD | 100.697% |